文献速递眼底病与葡萄膜炎

在年龄相关性黄斑变性治疗比较试验中,降眼压药物对新生血管性年龄相关性黄斑变性治疗结局的影响

EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS.
PubMed 文献 · Retina · 2019-01-01

该研究为年龄相关性黄斑变性治疗比较试验(CATT)的二次分析,评估连续2年使用增加房水流出药物(A组:局部前列腺素类)或抑制房水生成药物(B组:局部β受体阻滞剂和碳酸酐酶抑制剂)对治疗结局的影响。共纳入28例A组、19例B组和857例对照。结果显示,B组在抗VEGF治疗期间与视网膜厚度和总厚度更大程度降低及视力改善趋势相关,而A组未观察到类似程度的效果;因样本量小和二次分析性质,作者认为这些发现需谨慎解读,或许可作为未来前瞻性研究的基础。

要点

  • 连续2年使用抑制房水生成药物(B组)与抗VEGF治疗期间视网膜厚度和总厚度更大程度降低及视力改善趋势相关。
  • 使用增加房水流出药物(A组)未观察到与B组相同程度的效果。
  • 因样本量小和二次分析,作者认为这些发现需谨慎解读,或许可作为未来前瞻性研究的基础。

核心结论

  • 在新生血管性年龄相关性黄斑变性的抗VEGF治疗期间,合并使用房水抑制药物与2年内视网膜厚度和总厚度更大程度降低及视力结局改善的趋势相关。
  • 使用增加房水流出药物未观察到相同程度的效果。
  • 由于样本量小和二次分析,这些发现必须谨慎解读,或许可作为未来前瞻性研究的基础。

研究设计与样本

  • 年龄相关性黄斑变性治疗比较试验(CATT)数据的二次分析。
  • 审查用药记录,确定连续2年使用增加房水流出药物(A组:局部前列腺素类)或抑制房水生成药物(B组:局部β受体阻滞剂和碳酸酐酶抑制剂)的患者。
  • 排除使用混合机制降眼压药物或同时使用多个组别药物的眼。
  • 纳入28例A组患者、19例B组患者和857例对照(未使用降眼压药物)。
  • 比较各组在第1年、第2年及整个2年期间对治疗的眼解剖和视力反应与对照组的差异。

主要发现

  • 2年后,对照组平均视力较基线改善+6.3个字母,A组为+3.5个字母(P=0.38),B组为+13.8个字母(P=0.052)。
  • 2年后,对照组平均视网膜厚度较基线变化-54.9 μm,A组为-80.6 μm(P=0.26),B组为-96.8 μm(P=0.13)。
  • 2年后,对照组平均总厚度较基线变化-163 μm,A组为-180 μm(P=0.63),B组为-238 μm(P=0.08)。
  • 在调整基线值、抗VEGF药物和治疗方案的纵向分析中,B组较对照组视力改善更多(差异2.6个字母,95%CI:-3.4-8.5个字母)。
  • 在调整基线值、抗VEGF药物和治疗方案的纵向分析中,B组较对照组视网膜厚度降低更多(-17.9 μm,95%CI:-36.5至0.7 μm),总厚度较基线降低更多(平均差异-54.7 μm,95%CI:-103至6.2 μm)。

局限性

  • 样本量小。
  • 本研究为二次分析。
  • 作者指出这些发现必须谨慎解读,或许可作为未来前瞻性研究的基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effect of intraocular pressure-lowering medications on treatment outcomes in the Comparison of AMD Treatments Trials. METHODS: Secondary analysis of Comparison of AMD Treatments Trials data. Medication logs were reviewed for continuous 2-year use of agents that increased aqueous outflow (Group A: topical prostaglandins) or suppressed aqueous production (Group B: topical beta blockers and carbonic anhydrase inhibitors). Eyes were excluded if mixed-mechanism intraocular pressure-lowering agents or medications from more than one group were taken. Anatomical and vision responses to treatment at years 1, 2, and over the entire 2-year period in each group were compared with controls (no intraocular pressure-lowering medications). RESULTS: Inclusion criteria were met by 28 Group A patients, 19 Group B patients, and 857 controls. After 2 years, the control group had a mean visual acuity improvement of +6.3 letters from baseline, compared with +3.5 letters in Group A (P = 0.38), and +13.8 letters in Group B (P = 0.052). Mean retinal thickness change from baseline was -54.9 μm in controls, -80.6 μm in Group A (P = 0.26), and -96.8 μm in Group B (P = 0.13). Mean total thickness change from baseline was -163 μm in controls, -180 μm in Group A (P = 0.63), and -238 μm in Group B (P = 0.08). In longitudinal analysis with adjustment by their baseline values, anti-vascular endothelial growth factor treatment drug and regimen, Group B had more visual acuity improvement (difference of 2.6 letters, 95% confidence interval: -3.4-8.5 letters), more reduction in the retinal thickness (-17.9 μm, 95% confidence interval: -36.5 to 0.7 μm), and total thickness from baseline (mean difference of -54.7 μm, 95% confidence interval: -103 to 6.2 μm) compared with the control group. CONCLUSION: Concurrent aqueous suppressant use during anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration was associated with a trend toward greater reductions in retinal and total thickness as well as improved visual outcomes over 2 years. A similar effect was not observed to the same extent with agents that increase aqueous outflow. Because of the small sample size and secondary analysis, these findings must be cautiously interpreted and perhaps serve as a basis for future prospective studies.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Rahimy E, Ying GS, Pan W, et al. EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS. Retina. 2019. PMID: 29517580. doi:10.1097/IAE.0000000000002124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。